Daniel Vis
Overview
Explore the profile of Daniel Vis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
137
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Isebia K, de Jong A, van Dessel L, de Weerd V, Beaufort C, Helmijr J, et al.
Mol Oncol
. 2025 Mar;
PMID: 40084488
Cell-free circulating tumor DNA (ctDNA) has emerged as a promising biomarker for response evaluation in metastatic castration-resistant prostate cancer (mCRPC). The current study evaluated the modified fast aneuploidy screening test-sequencing...
2.
Vis D, Dumoulin E, Vakil E, MacEachern P, Samy L, Hergott C, et al.
J Bronchology Interv Pulmonol
. 2025 Jan;
32(2).
PMID: 39819787
Background: Diagnosis of sarcoidosis often involves endobronchial biopsy (EBB), but studies have shown varying yields for EBB in suspected sarcoidosis, partly due to differences in identifying abnormal mucosa under white...
3.
Zhu X, Farsh T, Vis D, Yu I, Li H, Liu T, et al.
J Clin Invest
. 2024 Oct;
134(19).
PMID: 39352383
BACKGROUNDAndrogen receptor signaling inhibitors (ARSIs) have improved outcomes for patients with metastatic castration-resistant prostate cancer (mCRPC), but their clinical benefit is limited by treatment resistance.METHODSTo investigate the mechanisms of ARSI...
4.
Desgagnes N, Senior L, Vis D, Alikhani K, Lithgow K
Endocrinol Diabetes Metab
. 2024 Apr;
7(3):e00476.
PMID: 38597588
Objective: Onset and exacerbation of autoimmune, inflammatory or steroid-responsive conditions have been reported following the remission of Cushing syndrome, leading to challenges in distinguishing a new condition versus expected symptomatology...
5.
Palit S, van Dorp J, Vis D, Lieftink C, Linder S, Beijersbergen R, et al.
Sci Rep
. 2021 Jul;
11(1):13683.
PMID: 34211036
Resistance to drugs targeting the androgen receptor (AR) signaling axis remains an important challenge in the treatment of prostate cancer patients. Activation of alternative growth pathways is one mechanism used...
6.
Vis D, Boucly A, Humbert M, Weatherald J
Eur Respir J
. 2020 May;
55(5).
PMID: 32409427
No abstract available.
7.
Palit S, Vis D, Stelloo S, Lieftink C, Prekovic S, Bekers E, et al.
Elife
. 2019 Dec;
8.
PMID: 31855178
Androgen receptor (AR) inhibitors represent the mainstay of prostate cancer treatment. In a genome-wide CRISPR-Cas9 screen using LNCaP prostate cancer cells, loss of co-repressor conferred resistance to AR antagonists apalutamide...
8.
Braganza M, Shaw J, Solverson K, Vis D, Janovcik J, Varughese R, et al.
Chest
. 2019 Mar;
155(5):982-990.
PMID: 30826305
Background: The usefulness of physical examination findings for pulmonary hypertension (PH) is not well established. The purpose of this study was to evaluate prospectively the diagnostic performance of the physical...
9.
Boorsma A, Foat B, Vis D, Klis F, Bussemaker H
Nucleic Acids Res
. 2005 Jun;
33(Web Server issue):W592-5.
PMID: 15980543
One of the key challenges in the analysis of gene expression data is how to relate the expression level of individual genes to the underlying transcriptional programs and cellular state....